QYUNS-B (02509) announced that Sino-American East China recently received the "Drug Registration Certificate" and "Drug Supplemental Application Approval Notice" issued by the National Medical Products Administration (NMPA). The marketing authorization application and supplemental application for Ustekinumab Injection (Intravenous Infusion) (brand name: Saijiening®) and Ustekinumab Injection (brand name: Sailexin®, R&D code: QX001S/HDM3001-2) for the treatment of Crohn's disease have been approved.